US FDA’s Biosimilars Group Will Conduct Some Supplement Reviews, Become ‘Like Another Discipline’
OTBB Aims To Facilitate Approval Of Short Turn-Around Supplements
Office of Therapeutic Biologics and Biosimilars Director Sarah Yim says in an interview with the Pink Sheet that more staff are being added to deal with labeling supplements.
You may also be interested in...
Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.
Popular characteristics like goal dates are expected to remain in place if Congress does not renew the user fee programs by 1 October.
Sen. Richard Burr introduces a reauthorization bill without any policy changes, even ones he previously endorsed, saying it’s the clearest path forward now.